Fulltext

Circulating cytokines and small molecules follow distinct expression patterns in acute myeloid leukaemia

Islam M 1 , Mohamed EH 2 , Esa E 3 , Kamaluddin NR 3 , Zain SM 2 , Yusoff YM 3 Show all authors , Assenov Y 4 , Mohamed Z 2 , Zakaria Z 3

Affiliations 

  • 1 Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
  • 2 Pharmacogenomics Lab, Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia
  • 3 Haematology Unit, Cancer Research Centre, Institute for Medical Research, Jalan Pahang, Kuala Lumpur 50588, Malaysia
  • 4 Computational Epigenomics Group, Division of Epigenomics and Cancer Risk Factor, German Cancer Research Center, Heidelberg 69120, Germany
Br. J. Cancer, 2017 Nov 07;117(10):1551-1556.
PMID: 28898234 DOI: 10.1038/bjc.2017.316

Abstract

BACKGROUND: Although aberrant expression of cytokines and small molecules (analytes) is well documented in acute myeloid leukaemia (AML), their co-expression patterns are not yet identified. In addition, plasma baselines for some analytes that are biomarkers for other cancers have not been previously reported in AML.

METHODS: We used multiplex array technology to simultaneously detect and quantify 32 plasma analyte (22 reported analytes and 10 novel analytes) levels in 38 patients.

RESULTS: In our study, 16 analytes are found to be significantly deregulated (13 higher, 3 lower, Mann-Whitney U-test, P-value <0.005), where 5 of them have never been reported before in AML. We predicted a seven-analyte-containing multiplex panel for diagnosis of AML and, among them, MIF could be a possible therapeutic target. In addition, we observed that circulating analytes show five co-expression signatures.

CONCLUSIONS: Circulating analyte expression in AML significantly differs from normal, and follow distinct expression patterns.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications